Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL

Ian W. Flinn, MD, PhD
Published: Tuesday, Dec 09, 2014



Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).

The study enrolled 34 patients who received duvelisib across a variety of doses. At the dose selected for phase III studies, 25 mg twice daily, duvelisib demonstrated an overall response rate (ORR) of 72%, notes Flinn. Thirty-three percent of patients experienced a complete response (CR). Among patients specifically with follicular lymphoma (n = 13), the ORR was 69%, including a 38% CR rate.

The treatment is currently being explored in the phase II DYNAMO trial and the phase III DYNAMO+R trial for patients with NHL. DYNAMO will asses duvelisib as monotherapy and DYNAMO-R will combined the novel therapy with rituximab.

<<< View more from the 2014 ASH Annual Meeting



Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).

The study enrolled 34 patients who received duvelisib across a variety of doses. At the dose selected for phase III studies, 25 mg twice daily, duvelisib demonstrated an overall response rate (ORR) of 72%, notes Flinn. Thirty-three percent of patients experienced a complete response (CR). Among patients specifically with follicular lymphoma (n = 13), the ORR was 69%, including a 38% CR rate.

The treatment is currently being explored in the phase II DYNAMO trial and the phase III DYNAMO+R trial for patients with NHL. DYNAMO will asses duvelisib as monotherapy and DYNAMO-R will combined the novel therapy with rituximab.

<<< View more from the 2014 ASH Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x